PMID- 27058430
OWN - NLM
STAT- MEDLINE
DCOM- 20170313
LR  - 20170313
IS  - 1873-5169 (Electronic)
IS  - 0196-9781 (Linking)
VI  - 79
DP  - 2016 May
TI  - Biochemical and biophysical combined study of bicarinalin, an ant venom 
      antimicrobial peptide.
PG  - 103-13
LID - S0196-9781(16)30053-5 [pii]
LID - 10.1016/j.peptides.2016.04.001 [doi]
AB  - We have recently characterized bicarinalin as the most abundant peptide from the 
      venom of the ant Tetramorium bicarinatum. This antimicrobial peptide is active 
      against Staphylococcus and Enterobacteriaceae. To further investigate the 
      antimicrobial properties of this cationic and cysteine-free peptide, we have studied 
      its antibacterial, antifungal and antiparasitic activities on a large array of 
      microorganisms. Bicarinalin was active against fifteen microorganisms with minimal 
      inhibitory concentrations ranging from 2 and 25μmolL(-1). Cronobacter sakazakii, 
      Salmonella enterica, Candida albicans, Aspergilus niger and Saccharomyces cerevisiae 
      were particularly susceptible to this novel antimicrobial peptide. Resistant strains 
      of Staphylococcus aureus, Pseudomonas aeruginosa and C. albicans were as susceptible 
      as the canonical strains. Interestingly, bicarinalin was also active against the 
      parasite Leishmania infantum with a minimal inhibitory concentrations of 2μmolL(-1). 
      The bicarinalin pre-propeptide cDNA sequence has been determined using a combination 
      of degenerated primers with RACE PCR strategy. Interestingly, the N-terminal domain 
      of bicarinalin pre-propeptide exhibited sequence similarity with the pilosulin 
      antimicrobial peptide family previously described in the Myrmecia venoms. Moreover, 
      using SYTOX green uptake assay, we showed that, for all the tested microorganisms, 
      bicarinalin acted through a membrane permeabilization mechanism. Two dimensional-NMR 
      experiments showed that bicarinalin displayed a 10 residue-long α-helical structure 
      flanked by two N- and C-terminal disordered regions. This partially amphipathic 
      helix may explain the membrane permeabilization mechanism of bicarinalin observed in 
      this study. Finally, therapeutic value of bicarinalin was highlighted by its low 
      cytotoxicity against human lymphocytes at bactericidal concentrations and its long 
      half-life in human serum which was around 15h.
CI  - Copyright © 2016 Elsevier Inc. All rights reserved.
FAU - Téné, Nathan
AU  - Téné N
AD  - Equipe EA 4357, VAcBio, Université de Toulouse, CUFR Champollion, Place de Verdun, 
      81012 Albi, France.
FAU - Bonnafé, Elsa
AU  - Bonnafé E
AD  - Equipe EA 4357, VAcBio, Université de Toulouse, CUFR Champollion, Place de Verdun, 
      81012 Albi, France.
FAU - Berger, Fanny
AU  - Berger F
AD  - Equipe EA 4357, VAcBio, Université de Toulouse, CUFR Champollion, Place de Verdun, 
      81012 Albi, France.
FAU - Rifflet, Aline
AU  - Rifflet A
AD  - Equipe EA 4357, VAcBio, Université de Toulouse, CUFR Champollion, Place de Verdun, 
      81012 Albi, France.
FAU - Guilhaudis, Laure
AU  - Guilhaudis L
AD  - Normandie Univ, COBRA, UMR 6014, IRIB, Université de Rouen, INSA de Rouen, CNRS, 
      IRCOF, 1 rue Tesnière, 76821 Mont-Saint-Aignan, France.
FAU - Ségalas-Milazzo, Isabelle
AU  - Ségalas-Milazzo I
AD  - Normandie Univ, COBRA, UMR 6014, IRIB, Université de Rouen, INSA de Rouen, CNRS, 
      IRCOF, 1 rue Tesnière, 76821 Mont-Saint-Aignan, France.
FAU - Pipy, Bernard
AU  - Pipy B
AD  - UMR 152-Pharma-Dev, Université de Toulouse, 31432 Toulouse, France.
FAU - Coste, Agnès
AU  - Coste A
AD  - UMR 152-Pharma-Dev, Université de Toulouse, 31432 Toulouse, France.
FAU - Leprince, Jérôme
AU  - Leprince J
AD  - Inserm U982, Laboratoire de Différenciation et Communication Neuronale et 
      Neuroendocrine, Equipe Facteurs Neurotrophiques et Différenciation Neuronale, 
      Plate-forme de Recherche en Imagerie Cellulaire de Haute-Normandie [PRIMACEN], IRIB, 
      Université de Rouen, 76821 Mont-Saint-Aignan, France.
FAU - Treilhou, Michel
AU  - Treilhou M
AD  - Equipe EA 4357, VAcBio, Université de Toulouse, CUFR Champollion, Place de Verdun, 
      81012 Albi, France. Electronic address: michel.treilhou@univ-jfc.fr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160404
PL  - United States
TA  - Peptides
JT  - Peptides
JID - 8008690
RN  - 0 (Ant Venoms)
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Antifungal Agents)
RN  - 0 (Antimicrobial Cationic Peptides)
RN  - 0 (Antiprotozoal Agents)
RN  - 0 (Insect Proteins)
RN  - 0 (bicarinalin, Tetramorium bicarinatum)
SB  - IM
MH  - Amino Acid Sequence
MH  - Animals
MH  - Ant Venoms/chemistry/genetics/metabolism/*pharmacology
MH  - Anti-Bacterial Agents/chemistry/metabolism/*pharmacology
MH  - Antifungal Agents/chemistry/metabolism/*pharmacology
MH  - Antimicrobial Cationic Peptides/chemistry/genetics/metabolism/*pharmacology
MH  - Antiprotozoal Agents/chemistry/metabolism/*pharmacology
MH  - *Ants
MH  - Base Sequence
MH  - Cell Membrane Permeability
MH  - Cell Survival/drug effects
MH  - Cells, Cultured
MH  - Conserved Sequence
MH  - Half-Life
MH  - Humans
MH  - Insect Proteins/chemistry/genetics/metabolism/pharmacology
MH  - Lethal Dose 50
MH  - Lymphocytes/drug effects/physiology
MH  - Microbial Sensitivity Tests
MH  - Models, Molecular
MH  - Phylogeny
MH  - Protein Structure, Secondary
MH  - Proteolysis
OTO - NOTNLM
OT  - Ant venom
OT  - Antimicrobial peptide
OT  - Candida
OT  - Leishmania
OT  - Prepropeptide
OT  - Salmonella
OT  - Therapeutic index [TI]
EDAT- 2016/04/09 06:00
MHDA- 2017/03/14 06:00
CRDT- 2016/04/09 06:00
PHST- 2016/02/18 00:00 [received]
PHST- 2016/03/31 00:00 [revised]
PHST- 2016/04/01 00:00 [accepted]
PHST- 2016/04/09 06:00 [entrez]
PHST- 2016/04/09 06:00 [pubmed]
PHST- 2017/03/14 06:00 [medline]
AID - S0196-9781(16)30053-5 [pii]
AID - 10.1016/j.peptides.2016.04.001 [doi]
PST - ppublish
SO  - Peptides. 2016 May;79:103-13. doi: 10.1016/j.peptides.2016.04.001. Epub 2016 Apr 4.
